United Therapeutics enrolls first patient in Phase 3 TETON 2 study of Tyvaso for IPF

UNITED THERAPEUTICS Corp

First patient enrolled in Phase 3 TETON 2 study of Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).
Study targets 396 adult IPF patients at sites outside the US and Canada; 52-week treatment evaluating forced vital capacity (FVC).
Tyvaso is already FDA-approved for PH-ILD but not for IPF without documented pulmonary hypertension.
TETON program builds on positive FVC impact observed in the INCREASE study of inhaled treprostinil in IPF patients with PH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.